| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
110,537,000 |
| Market
Cap: |
1.44(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$11.42 - $36.62 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 20.7 |
| Insider 6 Months : 20.7 |
| Insider 3/6 Months : 41.5 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe, rare muscle disorders. Co.'s primary product candidate, EDG-5506, is an orally administered allosteric, selective, fast myofiber (type II) myosin small molecule inhibitor designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. Using its proprietary drug discovery platform, Co. is developing a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address a range of genetically defined muscle disorders.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
993,542 |
993,542 |
993,542 |
1,913,489 |
| Total Buy Value |
$20,000,000 |
$20,000,000 |
$20,000,000 |
$30,100,948 |
| Total People Bought |
2 |
2 |
2 |
3 |
| Total Buy Transactions |
2 |
2 |
2 |
5 |
| Total Shares Sold |
15,949 |
70,000 |
519,953 |
845,111 |
| Total Sell Value |
$262,428 |
$1,826,482 |
$14,560,258 |
$18,745,694 |
| Total People Sold |
6 |
6 |
7 |
7 |
| Total Sell Transactions |
6 |
14 |
22 |
37 |
| End Date |
2025-04-03 |
2024-12-31 |
2024-07-02 |
2023-07-03 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Fox Jonathan C |
|
– • – |
2025-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
858 |
12,274 |
|
- |
|
| Moore John R |
General Counsel |
• – – |
2025-05-02 |
4 |
S |
$16.45 |
$31,757 |
D/D |
(1,930) |
6,531 |
|
24% |
|
| Donovan Joanne M. |
CMO |
• – – |
2025-05-02 |
4 |
S |
$16.45 |
$85,348 |
D/D |
(5,187) |
21,588 |
|
24% |
|
| Carruthers R Michael |
Chief Financial Officer |
• – – |
2025-05-02 |
4 |
S |
$16.45 |
$21,621 |
D/D |
(1,314) |
81,014 |
|
24% |
|
| Koch Kevin |
President and CEO |
• • – |
2025-05-02 |
4 |
S |
$16.45 |
$70,358 |
D/D |
(4,276) |
20,619 |
|
24% |
|
| Derakhshan Behrad |
Chief Business Officer |
• – – |
2025-05-02 |
4 |
S |
$16.45 |
$27,824 |
D/D |
(1,691) |
20,355 |
|
24% |
|
| Russell Alan J |
Chief Scientific Officer |
• • – |
2025-05-02 |
4 |
S |
$16.45 |
$25,520 |
D/D |
(1,551) |
18,521 |
|
24% |
|
| Moore John R |
General Counsel |
• – – |
2025-05-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,209 |
8,461 |
|
- |
|
| Donovan Joanne M. |
CMO |
• – – |
2025-05-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,417 |
26,775 |
|
- |
|
| Carruthers R Michael |
Chief Financial Officer |
• – – |
2025-05-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,209 |
82,328 |
|
- |
|
| Koch Kevin |
President and CEO |
• • – |
2025-05-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,417 |
24,895 |
|
- |
|
| Derakhshan Behrad |
Chief Business Officer |
• – – |
2025-05-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,209 |
22,046 |
|
- |
|
| Russell Alan J |
Chief Scientific Officer |
• • – |
2025-05-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,209 |
20,072 |
|
- |
|
| Thompson Peter A |
Director |
– • • |
2025-04-03 |
4 |
B |
$20.13 |
$10,000,000 |
I/I |
496,771 |
443,792 |
2.25 |
-6% |
|
| Orbimed Genesis Gp Llc |
Director |
– • • |
2025-04-03 |
4 |
B |
$20.13 |
$10,000,000 |
I/I |
496,771 |
443,792 |
2.25 |
-6% |
|
| Fox Jonathan C |
|
– • – |
2025-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
559 |
11,416 |
|
- |
|
| Koch Kevin |
President and CEO |
• • – |
2025-03-07 |
4 |
AS |
$30.00 |
$3,000 |
D/D |
(100) |
14,478 |
|
-53% |
|
| Koch Kevin |
President and CEO |
• • – |
2025-03-07 |
4 |
OE |
$0.18 |
$18 |
D/D |
100 |
14,578 |
|
- |
|
| Russell Alan J |
Chief Scientific Officer |
• • – |
2025-03-07 |
4 |
AS |
$30.02 |
$6,004 |
D/D |
(200) |
14,863 |
|
-53% |
|
| Russell Alan J |
Chief Scientific Officer |
• • – |
2025-03-07 |
4 |
OE |
$0.18 |
$36 |
D/D |
200 |
15,063 |
|
- |
|
| Russell Alan J |
Chief Scientific Officer |
• • – |
2025-02-06 |
4 |
AS |
$30.13 |
$36,153 |
D/D |
(1,200) |
14,863 |
|
-49% |
|
| Russell Alan J |
Chief Scientific Officer |
• • – |
2025-02-06 |
4 |
OE |
$0.18 |
$216 |
D/D |
1,200 |
16,063 |
|
- |
|
| Koch Kevin |
President and CEO |
• • – |
2025-02-06 |
4 |
AS |
$31.13 |
$28,018 |
D/D |
(900) |
14,478 |
|
-49% |
|
| Koch Kevin |
President and CEO |
• • – |
2025-02-06 |
4 |
OE |
$13.11 |
$11,799 |
D/D |
900 |
15,378 |
|
- |
|
| Derakhshan Behrad |
Chief Business Officer |
• – – |
2025-02-05 |
4 |
AS |
$30.03 |
$300,300 |
D/D |
(10,000) |
16,837 |
|
-51% |
|
177 Records found
|
|
Page 1 of 8 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.19 (1.48%) 
